Please login to the form below

Not currently logged in
Email:
Password:

Nektar Therapeutics

This page shows the latest Nektar Therapeutics news and features for those working in and with pharma, biotech and healthcare.

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. . ... Proving the

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Nektar Therapeutics’ CD122 agonist NKTR-214 posted mixed results in mid-stage trials alongside Opdivo in solid

  • Deal Watch September 2016 Deal Watch September 2016

    A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II ... 639. Cynapsus Therapeutics / Sunovion. Acquisition corporate.

  • Deal Watch June 2016 Deal Watch June 2016

    licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery). ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Christian Pangratz to head up Sterna Biologicals Christian Pangratz to head up Sterna Biologicals

    He has also held roles for Nektar Therapeutics, Bayer and Pfizer.

  • Nektar Therapeutics appoints Jeff Ajer Nektar Therapeutics appoints Jeff Ajer

    He joins as an independent director. California, US-based Nektar Therapeutics has appointed Jeff Ajer as its independent director to the company’s board of directors, following his 25 years’ of ... Howard Robin, president and CEO, Nektar Therapeutics,

  • Cubist’s Dr Lorianne Masuoka jumps ship to InVivo Cubist’s Dr Lorianne Masuoka jumps ship to InVivo

    Comes amidst MSD’s recent takeover of the antibiotic specialist. InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... Prior to her time at Cubist, she served in various roles of

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....

Infographics